Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Abstract Purpose To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. Patients and methods R-HCC patients who unde...

Full description

Bibliographic Details
Main Authors: Yusheng Guo, Yanqiao Ren, Lei Chen, Tao Sun, Weihua Zhang, Bo Sun, Licheng Zhu, Fu Xiong, Chuansheng Zheng
Format: Article
Language:English
Published: BMC 2022-03-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
Immune checkpoint inhibitors
TACE
Recurrence
Online Access:https://doi.org/10.1186/s12885-022-09325-6

Internet

https://doi.org/10.1186/s12885-022-09325-6

Similar Items